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Experimental allergic encephalomyelitis (EAE)' is an animal model of antigen-
specific,Tcell-mediated autoimmune disease . The characteristic clinical and histo-
logical features of chronic relapsing paralysis and demyelination with perivascular
mononuclear cell infiltration of the central nervous system (CNS) resemble human
multiple sclerosis (1, 2) . EAE is mediated by T cells of the helper phenotype (CD4+,
CD8 - , IL-2R+ ) as detected in the CNS lesions of EAE animals (3) . The involve-
ment ofCD4+ T cells is readily demonstrated by the transfer of MBP-specific T cell
lines andclones to rats (3, 4) and mice (5, 6) andby the fact that EAE can be treated
with antibody to CD4 but not to other T cell subsets or B cells (7) . EAE can be
actively inducedby immunization with synthetic peptides corresponding to different
regions of myelin basic protein (MBP), as well as with the whole molecule (5, 8) .
The ci-acetylated, NH2-terminal, nonapeptide ofMBP (1-9NAc) (identical in rat,
mouse, and human MBP) is the dominant encephalitogenic T cell epitope in the
PL/J and B10.PL (H-2u) mouse strains, eliciting rapid onset of disease (5). The en-
cephalitogenic peptide determinants vary in different MHC haplotypes (8, 9) . For
example, the disease-inducing T cell determinants for the SJL/J (H-25) strain have
recently been localized within the mouseMBP COOH-terminal region 81-104 (10) .
Activation ofTcells involves the recognition of bothMHC and peptide (11) . Thus,
EAE has been treated with mAbs toTCRV08 determinants (found on most T cells
directed to the dominant 1-9NAc determinant) (12, 13) and to MHC Ia molecules
(7). However, we wished to investigate the alternative of using antigen to tolerize
autoreactive T cells . Previous studies tolerizing animals against whole MBP have
been successful in preventing EAE (14, 15), suggesting that tolerance againstT cell
determinants might provide a specific approach toward therapy . Neonatal adminis-
tration of minimal immunogeniccytochrome and lysozyme peptides inIFA was pre-
viously shown to greatly reduce the adultT cell proliferative response, with exqui-
site peptide specificity (16, 17).
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Here, experiments are presented on mice tolerized during the neonatal period
to the 1-9NAc peptide. We investigated whether reduction in both the in vitro T
cell proliferation and disease assays would occur, after challenge of the tolerant mice
with 1-9NAc or MBP . This approach could show whether peptides might be used
for specific prophylaxis with the advantages of greater purity and potentially fewer
side effects than whole MBP (14, 15, 18, 19). It also enabled us to investigate toler-
ance to a dominant determinant on a self antigen that is normally sequestered from
the peripheral circulation, and does not induce tolerance by clonal elimination during
development (20, 21).
Materials and Methods
Mice.
￿
Male and female B10TL mice (5-6 wk old) were purchased from TheJackson Lab-
oratory (Bar Harbor, ME) and were maintained and bred in our animal facilities at UCLA.
Antigens.
￿
The synthetic peptide, cx-amino acetylated MBP, residues 1-9 (1-9NAc), was
kindly provided by the Cetus Corp. (Emeryville, CA) or synthesized as previously described
(10). The sequence of 1-9NAc is as follows: Acetyl-Ala-Ser-Gln-Lys-Arg-Pro-Ser-Gln-Arg.
MBP was isolated from mouse or rat brains (Pel-Freez Biologicals, Rogers, AR); delipida-
tion was followed by acid extraction and analysis by SDS-PAGE (22). Hen eggwhite lysozyme
(HEL), 5 x crystallized, was obtained from Societa Prodotti Antibiotici (Milan, Italy). This
was additionally purified by elution as a single peak from a BioRex-70 column (Bio-Rad Labora-
tories, Richmond, CA) in 0.2 M sodium phosphate buffer at pH 7.18.
Bordetella Pertussis.
￿
B. pertussis organisms were provided as a generous gift by Dr. Robert
Fritz (Emory University, Atlanta, GA) and also purchased from the Michigan Department
ofPublic Health (Lansing, MI). Purified pertussigen was purchased from Porton Products Ltd.
(Porton Down, UK).
Tolerance Induction.
￿
Neonatal mice were injected intraperitoneally, according to a previous
protocol (16), at 24 and 72 h afterbirth with 50 1,1 containing either 14 nmol (15 Wg) of 1-9NAc,
or 7 nmol (100 tig) of HEL, emulsified 1 :1 with IFA (Gibco Laboratories, Grand Island, NY).
EAE Induction and Grading.
￿
AdultB10.PL mice (7-11 wk old) were immunized subcutane-
ously in the tail base with a 100-p,l mixture containing 100 Kg of 1-9NAc or 200 gg of rat
MBP, emulsified 1 :1 in CFA. Subsequently, either 10'° heat-killed B. pertussis (extensively
washed in saline) or 0.025 lAg ofpurifiedpertussigen (in 100 pl saline) were given intravenously
24 and 72 h later. (Both preparations were used during the course of these experiments and
were found to be equally effective.) Animals were observed daily and graded as follows: 1,
loss of tail tone; 2, hind limb weakness; 3, difficulty turning over, severe limb weakness or
mild paralysis; 4, severe to total paralysis; 5, dead.
T Cell Proliferation Assays.
￿
Adult B10.PL mice (7-11 wk old) were immunized subcutane-
ously (tail base) with 100 pl containing: 20 ILg of 1-9NAc or 100 leg of mouse MBP in saline,
emulsified 1 :1 in CFA. 10 d later, draining lymph node cells (LNC) were removed and tested
for proliferation according to a previous protocol (16): cells were cultured for 5 d with an-
tigens at concentrations ranging from 0.03 to 30 p.M, in HL-1 serum-freemedium (Ventrex
Laboratories, Portland, ME) supplemented with 2 mM glutamine, 100 U/ml penicillin, and
100 /Ag/ml streptomycin. 1 FtCi [3H]thymidine was added for the last 16 h of culture and the
incorporation was measured by scintillation counting.
Results
MBPPeptide 1-9NAc IsaMajor TCellEpitopeinBI0.PLMice.
￿
To establish peptide-
induced EAE in B10YL mice, we first demonstrated that in this strain 1-9NAc is
a dominant T cell determinant on MBP (Table I). After immunization of normal
adult mice with mouse MBP, an in vitro proliferative response is obtained to itself
and to the 1-9NAc determinant: the in vitro response to 1-9NAc is stronger thanCLAYTON ET AL.
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TABLE I
1-9NAc Is the Dominant Proliferative Epitope on MBP
in the B10.PL (H-2°) Mouse Strain
In vitro antigen
Antigen MBP
￿
1-9NAc
priming
￿
3 uM
￿
0.3 pM
￿
30 1AM
￿
3 ttM
￿
PPD
MBP
￿
19 .2 ± 12.8' 10.3 ± 8.1
￿
69.4 t 20 .8
￿
45 .5 t 14.1
￿
91 .8 t 6.6
1-9NAc
￿
2 .7 f 1 .5
￿
7.2 ± 0.3
￿
39.2 t 2.1
￿
7 .1 t 2.3
￿
104.6 f 4.2
" Values represent the mean [3H]TdR uptake oftriplicate cultures (x 10-3 t SD). [3H]TdR
incorporation is expressed as counts per minute, with background (media alone) values be-
tween 1 and 3 x 103) subtracted (Acpm). Adult mice were immunized with either mouse
MBP/CFA (100 jug/100 ul) or 1-9NAc/CFA (20 Wg/100 ul) subcutaneously in the base of
the tail. LNC were harvested 10 d later for proliferation assay. The antigen concentration
range used was 3-30 p.M for 1-9NAc and 0.3-3 pM for mouse MBP.
to whole MBP at the 3-LM dose. (For MBP a greater dose than this appears to be
toxic.) Likewise, good in vitro proliferation to MBP and 1-9NAc can be induced
by immunization with the 1-9NAc determinant itself. These results are consistent
with those of Zamvil et al. (5) sh6wing that 1-9NAc is a major proliferative T cell
determinant on MBP. It wasapparent that individual mice varied in their response
to MBP and 1-9NAc. For example, in vitro proliferation to MBP was undetectable
in one-thirdofmice immunizedwith MBP, although aresponse to 1-9NAc was seen
in the same animals (data not shown).
B10.PL Mice Can Be Neonatally Tolerized to the SelfPeptide 1-9NAc.
￿
To determine
iftolerance could be induced to the selfMBP peptide 1-9NAc, we used the protocol
previously described for induction of neonatal tolerance to cytochrome and lyzo-
zyme peptides (16, 17). The proliferative T cell response to 1-9NAc was consider-
ably lower within 1-9NAc-primed LNC in peptide-tolerized mice compared with
theproliferation in LNC from HEL-tolerizedmice (Fig. 1 A). Likewise, the 1-9NAc
response ofwhole MBP-primed LNCwas reduced in 1-9NAc-tolerizedmice, in con-
trast to HEL-tolerized control animals (Fig. 1 B).
The Immunodominant 1-9NAc Epitope Tolerizes the In VitroResponse to WholeMBP.
￿
Simi-
larly, in mice tolerized to 1-9NAc and immunized with mouse MBP, the in vitro
LNG proliferation to mouse MBPwasvirtually eliminated (Fig. 1 C). Mouse MBP
wasused in preference to rat MBP in these invitro studies, assuming crossreactivity
of amino acid sequences ofthe encephalitogenic determinants. The 1-9NAc deter-
minant for example is identical between these two species and although heterolo-
gous MBP may be used to activate autoreactive T cells, the pathogenic activity is
specificallyagainst selftissue. Inparticular, we wished to avoid proliferation induced
by epitopes specific to rat MBP (5). Again, variation between individual animals
was apparent, reflecting that found in normal mice. For example, two ofsix HEL-
tolerized mice did not respond to MBP (Fig. 1 C.
Induction ofEAE in BIO.PL Mice.
￿
Chronic relapsingEAE wasestablishedin B10TL
mice (H-2u) by immunization with the synthetic peptide 1-9NAc. The incidence
ofEAEin normal untreated B10.PLmice is shown inTable II. 100p.g ofthe peptide
1-9NAc is more efficient in causing disease than 200 jig ofnative rat MBP The
peptide results in much higher average severity and earlier mean day of onset of1684
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FIGURE 1.
￿
In vitro tolerance induced by 1-9NAc. Mice were tolerized by injection at 24 and
72 h after birth with 50 Al containing 14 nmol of 1-9NAc/IFA. Adults were then immunized
with either 1-9NAc/CFA (20 pg/100 Al) or mouse MBP/CFA (100 pgll00pl) subcutaneously in
the base ofthe tail. LNC were harvested 10 days later for proliferation assay as described in the
legend to Table 1. In vitro proliferation was tested to 1-9NAc at an optimal concentration of
30 AM (A and B) or MBP at 3 AM (C). The arithmetic mean of the antigen-specific response
for each group is represented by ahorizontal bar. The symbols are as follows: (O) control, HEL-
tolerized mice, immunizedwith 1-9NAc (A) or mouseMBP(B and Q; filled triangles (A) repre-
sent 1-9NAc tolerized mice immunized with 1-9NAc (A) or mouse MBP (B and C).
disease, 3.2 and 12.6 d, respectively, compared with 1.3 and 17.5 d, for the whole
molecule. The characteristic disease course of three mice is shown in Fig. 2. This
pattern is similar to that described for PL/J, SJL, and (PL/J x SJL)F1 mice (5).
The patternof diseaseseverity varied forindividual animals, although interestingly,
most relapses tended to occur simultaneously.
TABLE II
EAE Is Induced in Normal BIO. P L Mice after Immunization
with 1-9NAc and Rat MBP
' Disease incidence is expressed as the number of animals showing clinical signs of EAE/the
total number per group. Animals were immunized for EAE by injection of the above dose
of antigen in CFA, given 1010 B. pertussis in saline intravenously at 24 and 72 h, then moni-
tored daily.
$ The disease score indicates the average of the maximum severity scores for each diseased
animal per group. Mice were graded as follows: 1, loss of tail tone; 2, hind limb weakness;
3, difficulty turning over, severe limb weakness or mild paralysis; 4, severe to total paralysis;
5, dead.
4 The total group score indicates the sum ofmaximum disease scores/total number of animals
per group.
Immunogen Dose
Disease
incidence'
Disease
score$
Total
group scores
Mean day
of onset
h8
1-9NAc 100 14/16 (86.5%) 3 .2 t 1 .1 2.8 ± 1 .3 12.6 t 3 .6
Rat MBP 200 4/5 (80%) 1 .3 t 0.4 1 .0 t 0.3 17.5 t 9.3c.
O
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b
u
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Neonatal Toleranceto 1-9NAcSuccessfully DecreasestheIncidenceof1-9NAc-inducedEAE
￿
A
considerable reduction in disease incidence was found inmice tolerized to 1-9NAc,
and subsequently immunized with the same peptide in adulthood (Table III). This
is approximately halfofthat seen in control, HEL-tolerized mice andis statistically
significant (according to X2 analysis with Yates correction factor (p is 0.05)). In those
1-9NAc-tolerized mice that did get EAE, the disease score (the average maximum
score ofdiseased animals) was one full grade lower. The total group score, including
all animals (with and without EAE), clearly expresses this difference in disease ac-
tivity with a score of0.8for all 1-9NAc-tolerized mice and 2.7 for theHEL-tolerized
controls. Also there appeared to be a correlation between reduced incidence and
meanday ofonset forclinical disease, which was later (day 14) for 1-9NAc-tolerized
mice than for HEL-tolerized controls (day 11.9). Fig. 3 illustrates the absence of
EAE in themajority of1-9NAc-tolerized mice followingimmunization with 1-9NAc.
It also shows the tendency ofdiseased animals in the tolerized group to have lower
grade symptoms than controls.
To improve the degree oftolerance, we are investigating several parameters such
as dose of tolerogen or age of challenge, but most importantly, using 1-11NAc as
thetolerogen. This MBP 1-11 peptide appearstobe moreimmunogenic than 1-9NAc
(5); tolerization with 1-11 may more effectively eliminate T cells ofall affinities that
bind 1-9NAc.
Failure to Suppress MBP-induced EAE in Mice Tolerized to 1-9NAc.
￿
Immunization
of 1-9NAc-tolerized mice with rat MBP produces EAE in the same proportion of
animals (50%) as in the control, HEL-tolerized groups (Table IV). The difference
Disease
￿
Disease
￿
Total
￿
Mean day
Tolerogen
￿
Antigen
￿
incidence'
￿
scorel
￿
group scores
￿
of onset
1-9NAc
￿
1-9NAc
￿
9/23 (397 .)
￿
2 .1 t 1 .1
￿
0.8 f 0.9
￿
14.0 t 3.8
HEL
￿
1-9NAc
￿
17/20 (85%)
￿
3 .1 f 1 .2
￿
2.7 f 1 .0
￿
11 .9 t 2.4
See footnotes for Table II.
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TABLE III
Tolerance to EAE Induction Is Achieved in BI0. PL Mice
Treated Neonatally with 1-9NAc
FIGURE 2.
￿
Chronic relapsing paralysis in-
duced in 3 B10.PL mice. Mice were im-
munized with 1-9NAc/CFA, given B. per-
tussis in saline intravenously at 24 and 72
hours, then monitored daily. Disease sever-
ity was graded from 1 to 5 as described
in Table II.1686
￿
TOLERANCE TO MAJOR DETERMINANT ON MYELIN BASIC PROTEIN
15
u
E
`o
E
C
10
5
0
maximum disease score
FIGURE 3 .
￿
Maximal disease severity in
neonatally tolerized mice. Mice were toler-
ized with 1-9NAc/IFA as described in Fig.
1, then immunized for disease and graded
for signs of EAE as outlined in the legend
to Table II. Open bars represent 1-9NAc-
tolerized animals; closed bars represent
control, HEL-tolerized animals.
in disease incidence between rat MBP-primed mice in Table II and HEL-tolerized
animals in Table IV may be due to variation between the different MBP prepara-
tions used. The less efficient disease induction in rat MBP-immunized mice (com-
pared with mice given 1-9NAc) can presumably be remedied by a higher dose. It
is clear, however, that even at this limiting dose, tolerance to 1-9NAc did not alter
the disease incidence. This shows that there is at least oneadditional disease-inducing
determinant on rat MBP, otherthan 1-9NAc, which crossreacts withthe autologous
protein at the T cell level.
Peptide31-50 Contains aSecond DiseaseDeterminant onMBP.
￿
The possible existence
of T cell determinants overlapping peptic cleavage sites of MBP (for example, at
residue 37 [23]) was tested using peptides spanning the whole MBP molecule. We
found that the peptide 31-50 (crossreactive between mouse and rat MBP) can nor-
mally induce strong LNC proliferation inthe B10.PL strain (Kono, D., unpublished
results). However, unlike the 1-9NAc determinant, there is no detectable in vitro
response to peptide 31-50 after priming with the whole MBP molecule.
In experiments with 1-9NAc- and control, HEL-tolerized mice, T cell prolifera-
tion to peptide 31-50 is equivalent in LNC from both groups (accounting for in-
dividual responsevariation) (Fig. 4). This isan indication ofspecificity ofthe peptide-
inducedtolerance. We also have data showing that MBP peptide 31-50 causes EAE
in B10.PL mice (Kono, D., unpublished results). This is consistent with the results
ofothers describing a Tcell proliferative and encephalitogenic determinant between
residues 35-47 on MBP for PL/J and (PL/J x SJL/J)F1 mice (24).
Thesedata suggest that in comparison to 1-9NAc, peptide 31-50 represents asub-
TABLE IV
Tolerance to 1-9NAc Has No Effect on EAE Induction in B10.PL Mice
after Immunization with Rat MBP
Disease
￿
Disease
￿
Total
￿
Mean day
Tolerogen
￿
Antigen
￿
incidence`
￿
scorel
￿
group scores
￿
of onset
1-9NAc
￿
rat MBP
￿
8/16 (50%)
￿
2.4 ± 1 .1
￿
1 .2 t 1 .3
￿
12 .9 ± 4.4
HEL
￿
rat MBP
￿
5/10 (50%)
￿
2.6 t 0.9
￿
1 .3 t 1 .4
￿
13 .6 t 3.3
See footnotes for Table II .1687
FIGURE 4. In vitro proliferation to
MBP peptide 31-50 in 1-9NAc- and
HEL-tolerized mice. Mice were im-
munizedwith peptide 31-50/CFA(20
Ag/100 Wl) subcutaneously in thebase
of the tail. LNC were harvested 10 d
laterforproliferation assayas described
in the legend to Table I. In vitro pro-
liferation was tested to peptide 31-50
at an optimal concentration of30 uM.
(O)Control, HEL-tolerizedmice; (A)
1-9NAc-tolerized mice.
dominant T cell determinant on MBP, but may be relevant to in vivo disease ac-
tivity. We are therefore examining whether peptide 31-50 includes the determinant
causing EAE in those 1-9NAc-tolerized mice which were subsequently challenged
with rat MBP
Discussion
Normal adult B10.PL mice mount a good proliferative response in vitro to MBP,
and this response appears to be predominantly directed against a determinant on
the NH2-terminal peptide, 1-9NAc (Table I). Tolerance induced in neonatal mice
to this peptide, greatly reduces not only the response to the peptide itself but also
the response to the whole protein (Fig. 1). This confirms theimmunodominant status
of the 1-9NAc determinant in the proliferative response. Indeed, 1-9NAc is also
the predominant EAE-inducing peptide in B10.PL mice (Table II), and neonatal
tolerance induced to 1-9NAc leads to a specific reduction in incidence and severity
of peptide-induced EAE (Table III) . However, in contrast to the lack of a prolifera-
tive response to MBP in 1-9NAc tolerant mice (Fig. 1), MBP induces disease in
these animals at the same frequency and to an equal severity, as in control mice
(Table IV). This suggests that one or more additional disease-inducing determinants
exist for H-2u mice. EAE-inducing activity appears to be a more sensitive assay than
in vitro proliferation fordetecting T cell responses specific forminordeterminants.
Experiments in a variety of systems indicate that a hierarchy of responsiveness
exists to a multideterminant antigen at the T cell level, in which the proliferative
response appearsto be limited to a few dominant determinants. Other potential (sub-
dominant)determinants existthat are only revealed by peptide immunization (10, 25,
26). It is possible that the hierarchy of determinants defined by disease induction
could be different from that defined by the in vitro proliferation assay. However,
this would seem unlikely and instead we would assume that the apparent difference
is one of sensitivity. There are several possible reasons why a subdominant deter-
minant maybe capable of inducing disease but not a proliferative response. For ex-
ample, theseautoreactive clones mayaccumulate within the CNS leavinglownumbers
remaining in the periphery, precluding their detection by the proliferation assay.
One possible candidate for an additional disease-inducing determinant on MBP
exists on peptide 31-50. This determinant is subdominant in the proliferative re-
70
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sponse in that no response to it is observed after MBP immunization, but a good
response is obtained after priming with peptide 31-50 itself. Peptide 31-50 can also
induce disease. A similar result, using the MBP peptide 35-47, has been found by
others (24). 35-47 induces a good proliferative response to itself as well as disease
in susceptible PL/J mice. This peptide determinant is only a minor component in
the anti-MBP T cell proliferative response,judging by the low frequency of 35-47-
specific T cell clones compared with 1-9-specific ones (27).
A panel of synthetic peptides, overlapping in sequence and spanning the whole
molecule, is being analyzed both in vivo and in vitro for the purpose of identifying
all encephalitogenic determinants in the H-2u haplotype. In the previous work of
others, no additional disease determinants were detected in synthetic peptides span-
ning amino acids 1-37 of rat MBP (5), although B10,PL mice gave aT proliferative
response to all fragments of guinea pigMBP (1-37, 43-88, and 89-169 [28]). Peptic
digestion of the MBP molecule at thesecleavage sites (residues 37 and 88) mayhave
destroyed otherdominant or subdominant encephalitogenic determinants (22). Since
in vitro proliferation studiesalone clearly do not indicate all disease-inducing Tcell
determinants on a self antigen, the neonatal tolerance system in EAE is ideal for
addressing these questions.
Our data suggest that B10.PL mice do not spontaneously develop autoimmune
encephalomyelitis, owing to the sequestration of MBP from the immune system.
Clearly autoreactive T cells are not deleted in these animals, but normally they are
not activated. These T cells can be tolerized by administration of peptide to neo-
natal mice. Presumably neonatal exposure to exogenous peptidecauses inactivation
or deletion as has been proposed in neonatal tolerance to cytochrome and lysozyme
peptides (16, 17). The ability to inactivate 1-9NAc-reactive cells shows that lack of
tolerance is not primarily due to an insensitivity of the T cells; rather it suggests
absence of MBP determinants from thedeveloping thymus (20, 21). This may result
from insufficient quantities of MBP in neonatal mice to reach the thymus and in-
duce tolerance (29).
In the normal adult, the blood-brain barrier usually will prevent trafficking of
significant numbers of autoreactive T cells through the CNS; this is in contrast with
more extensive trafficking during the autoimmune state (30-33). Additionally, the
presentation of MBP in an immunogenic form within theCNS may only occurwhen
class II expression is abnormally induced (33-35). As a consequence, competent,
but normally unstimulated MBP-specific T cells could be always present in the adult
animal. This last view is supportedby the finding that EAE can be induced in mice
with autologous MBP (28). In addition, in previous studies with the SJL strain,
the in vitro proliferative T cell response to autologous MBP was as strong as to the
heterologous protein (Kono, D., unpublished results).
Recently, EAE induction by MBP peptide 1-11 and whole MBP was partially
prevented in PL/J and B10.PL mice by treatment with an antibody specific for the
TCRV08 gene segment. This V08 gene segment was foundto be used in ti70-80%
of T cells recognizing the 1-9NAc determinant (12, 13, 36). T cell tolerization with
peptide epitopes, as shown here, has the advantage of greater specificity than V08-
targeted elimination andfurthermore addressesall cells with specificity for 1-9NAc,
including those using other TCR genes. Our data, emphasizing the role of addi-
tional determinants other than 1-9NAc, suggest that those mice immunized with
whole MBP that developed symptoms after antiV/O8 therapy were probably reactingto non-1-9NAc epitopes. The response to peptide 35-47, which is I-E° restricted,
is largely composed of T cells not expressing V08 (24).
For the purpose of eventual human treatment, it would be of crucial importance
to attempt to turn offdisease in the preimmunized mouse. Through the tolerance
mechanism, even selected T cellsofhigh affinity should be able to be rendered tolerant.
Peptide-induced tolerance hastheadvantagethat it minimizes the potentialside effects
of therapy with whole MBP (14, 15, 18, 19). Administration of tolerogenic peptides
might be attempted in various ways. For example, Higgins and Weiner (19) have
induced oral tolerance to MBPand MBP peptides in rats andhave successfully tolerized
T cells throughout the animal despite the localized nature of the stimulus. A large
dose ofantigen maybe needed to induce oral tolerancealthough this would not neces-
sarily be a contra-indicationifpeptide-induced tolerance were long lasting. A second
approach might be that used by Jenkins and Schwartz (37) for their in vitro induc-
tion of unresponsiveness in T cell clones (which actually can be regarded as repre-
sentative of activated cell populations) . Thus, ECDI-fixed spleen cells pulsed with
peptide may be excellent inducers of tolerance.
The failure to induce tolerance to whole MBP after tolerization with the major
encephalitogenic determinant 1-9NAc showed that subdominant disease-inducing
determinants can play a significant role in autoimmune disease. The diversity of
potential responses to MBP may provea majorobstacle to the use ofeither peptides
(for tolerance induction) or antiTCR antibodies for the elimination of self-reactive
T cells. However, with attention to the caveats discussed above, it is realistic to pre-
dict that peptide-induced tolerance is potentially a successful approach to the treat-
ment of autoimmune disease.
Summary
Experimental allergic encephalomyelitis (EAE) is a model of antigen-specific T
cell-mediated autoimmune disease. The a-acetylated, NH2-terminal nine amino
acids (1-9NAc) of myelin basic protein (MBP) represents the dominant T cell epi-
tope for the induction of EAE in the B10.PL (H-2°) strain.
We tolerized neonatal B10.PL mice to 1-9NAc and studied the proliferative re-
sponses to this peptide and to whole MBP Mice exposed to 1-9NAc in the neonatal
period were tolerant to subsequent challenge at the proliferative T cell level. Simi-
larly, in the 1-9NAc-tolerant group, both the incidence and severity of 1-9NAc in-
duced EAE were greatly reduced. The fact that we were able to tolerize mice nor-
mally responsive to MBP suggests that this self antigen is sequestered (within the
central nervous system) and hence tolerance to it is not normally induced.
No significant difference in disease incidence was seen in response to rat MBP
between control animals and 1-9NAc-tolerized mice (50% in both groups), demon-
strating the presence of at least one additional encephalitogenic determinant else-
where on the molecule.
We have successfully prevented disease induction by peptide-induced tolerization.
Tolerance induction by peptides provides a new and specific strategy in the preven-
tion of autoimmunity. However, it will be clearly necessary to fully define all epi-
topes potentially capableofinducing pathogenic Tcellsto ensure complete andeffective
therapy of T cell-mediated autoimmune disease.
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